Nicholls SJ, Bhatt DL, Buse JB et al (2023) Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics
[1] However, severe or persistent symptoms, signs of pancreatitis (severe abdominal pain radiating to the back), symptoms of thyroid tumors (neck mass, difficulty swallowing, persistent hoarseness), or allergic reactions (rash, itching, difficulty breathing) require prompt medical evaluation
Surgery, typically laparoscopic excision, removes visible lesions
Giver Malthe Hviid Christoffer Schilling Alexandra Zamorski Andreas Jensen Maria Gefke Heidi Storgaard Peter S
Consistency in Dosing : Keeping to the same semaglutide dose is key